marked increases in mature cells of other lineages. In vitro agar culture of bone marrow cells before GM-CSF treatment showed a normal number of granulocyte colonies; however, maturation was limited to the metamyelocyte stage. Although the absolute number and cycling rates of myeloid colony forming cells (predominantly eosinophils) increased after treatment, the maturation defect in the neutrophilic series persisted. The finding that GM-CSF induced stimulation of proliferation, which was coupled with maturation in the eosinophilic and monocytic but not the neutrophilic components, suggests that this patient had an intrinsic cellular or humoral defect in neutrophil maturation. 0 1990 by The American Society of Hematology.
been cloned and expressed in bacterial, fungal, and mammalian cell systems." We and others have demonstrated that recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a potent stimulator of myelopoiesis in vivo in patients with acquired immunodeficiency syndrome, myelodysplastic syndrome, aplastic anemia, lymphoproliferative disorders, acquired agranulocytosis, and in patients who have received chemotherapy or autologous bone marrow transplant^.'^-'^ In an attempt to stimulate granulopoiesis in a patient with severe CN, we gave the patient recombinant human GM-CSF as part of a phase I trial. To further understand the biologic basis for the disease and its response to this hormone, we have investigated the morphology of bone marrow, in vitro agar growth patterns of hematopoietic progenitor cells, and functions of circulating phagocytes before and after GM-CSF treatment in this patient. Our findings demonstrate that while GM-CSF stimulated myelopoiesis along eosinophilic and monocytic pathways, it did not correct the underlying maturation defect in the neutrophilic series in this patient.
CASE REPORT
A 13-year-old boy with severe C N was referred to The University of Texas M.D. Anderson Cancer Center for treatment with GM-CSF. The patient had developed omphalitis at 3 weeks of age. Neutropenia was diagnosed a t that time. He had since experienced recurrent infections, including cavitary pneumonia, chronic otitis media, lymphadenitis, recurrent cellulitis, chronic perianal abscess, necrotizing enterocolitis requiring a hemicolectomy, chronic periodontitis, stomatitis, and mucosal ulcers. Physical examination revealed severe peridontal disease, gingival hypertrophy, mucosal ulcers, and a perianal abscess.
GM-CSF (Immunex Corporation, Seattle, WA) treatment was initiated at 120 pg/m2/d) (specific activity of 5 x 10' colony-forming units per milligram of protein), given by continuous intravenous infusion through a central venous catheter for 2 weeks followed by discontinuation of GM-CSF Board. T h e patient was informed that blood and bone marrow samples were obtained for research purposes, and that his privacy would be protected.
As shown in Fig 1, the treatment was associated with a significant elevation in his white blood cell count (from a baseline of 3.2 x 103/pL to a maximum of 17.4 x 103/pL). T h e increase consisted mainly of eosinophils (from 0.224 x 103/pL to 13.05 x 103/pL) and monocytes (from 0.256 x 103/pL to 1.305 x 103/pL), rather than segmented neutrophils and bands (from 0.064 x 103/pL to 0.798 x lo3/ pL). T h e patient received six cycles of treatment, and the pattern of white blood cell response was similar with each cycle. During this time, resolution of the perianal abscess and mucosal ulcers in the oral cavity (Fig 2) were observed. T h e patient experienced two episodes of catheter-related infections (Staphylococcus epidermidis and Pseudomonas aeruginosa bacteremia), which responded to intravenous antibiotics and removal of the central venous catheter. Treatment with GM-CSF was well tolerated with minimal constitutional symptoms. Despite significant eosinophilia, no cardiac or pulmonary toxicities or vasculitis were seen.
METHODS
Peripheral blood, bone marrow aspirates, and biopsy specimens were processed by conventional methods. For ultrastructural morphology, the cells were fixed in phosphatebuffered 2.5% gluteraldehyde. Myeloperoxidase cytochemistry was performed according to the procedure of Graham and Karnovsky. 20 The cells were then postfixed in 2% osmium tetroxide, dehydrated in acetone, and embedded in Epon. Thin sections were stained with uranyl acetate-lead citrate and examined with a Jeol 1200 EX electron microscope at 60 kV.
All morphometric studies were carried out with Sigma Scan Computer software (Jandel Scientific). The bone marrow cellularity was measured on biopsy sections with a camera lucida device and a light microscope (100 x field). The number and diameter of granules Morphology of cells. 
Neutrophils
N Eosinophils W Basophils in bone marrow granulocytic and monocytic cells from the patient as well as control were determined using electron micrographs, all taken at the same calibrated magnification (6000~).
The assays for granulocyte-macrophage progenitor cells (CFU-GM) were performed as described previously.*' Briefly, bone marrow cells were separated into a low-density fraction using Hypaque-Ficoll and plated at 1 x lo5 cells per milliliter in semisolid medium with or without exogenous growth factors, such as 10% vol/vol 5637 human cell line conditioned medium (CM) or 100 units/mL recombinant human GM-CSF. Colonies (greater than 40 cells per aggregate) and clusters (3 to 40 cells per aggregate) derived from granulocytemacrophage progenitor cells were scored after 7 and 14 days of incubation. The percentages of bone marrow CFU-GM in DNA synthesis (the S-phase of cell cycle) were measured by a high-specificactivity, tritiated-thymidine kill technique. Morphologic examination of myeloid colonies was performed in situ after fixation with 5% glutaraldehyde, methanol dehydration, and staining with Luxol-fast blue and Harris' hematoxylin."
Phagocytic cells from the patient were purified by Hypaque-Ficoll gradient separation, dextran sedimentation, and hypotonic lysis. Blood samples obtained from normal volunteers served as paired controls. For control experiments, eosinophils and neutrophils were purified from adult control donors,23 and their chemotactic responses and H,O, production rates were compared as described below. Chemotaxis was assessed using a modified under-agarose assay in quadrupli~ate.~~ Four locomotive stimuli were examined: Hanks' balanced salt solution (HBSS), zymosan-activated serum (ACS), 5 x lo-' mol/L f-met-leu-phe (fMLP), and a mixture of activated serum plus fMLP.
H,02 production was quantitated by measuring scopoletin oxidation24 by phorbol myristate acetate (20 ng/mL)-stimulated cells in duplicate. The rate of H202 production was calculated from the observed rates of H,02 production produced by known amounts of glucose and glucose oxidase. Phagocytosis was quantitated using heat-killed Staphylococcus aureus as the phagocytic target. Purified cells (1 x 106/mL final) were combined with autologous serum (10% final) and staphylococci (1 x 108/mL final) and were tumbled at 37OC for 30 minutes. At 0, 15, and 30 minutes, aliquots were removed, combined with 11 units of lysostaphin (Sigma Chemical 
RESULTS
Bone marrow morphology. Before GM-CSF treatment, light microscopic studies of the bone marrow biopsy revealed 60% cellularity. The aspirate showed a shift to the left in the myeloid elements, which consisted mainly of promyelocytes and myelocytes, and a decrease in the mye1oid:erythroid cell ratio to 0.81.
Electron microscopic examination of the bone marrow aspirate ( Figs 3A and B) showed a predominance of promyelocytic cells in the myeloid series. The majority of promyelocytes were normal in appearance with a cell size of 10 to 15 pm in diameter, eccentrically located nucleus, vacuoles, prominent Golgi, abundant profiles of rough endoplasmic reticulum (RER), and numerous round peroxidase-positive primary granules (347 f 28 nm [mean f SD] diameter). However, several promyelocytes appeared dysmorphic and contained fewer primary granules than normal control promyelocytes did at the same stage of development (48 f 16 versus 79 8, respectively). In these promyelocytes, 5% to 25% of the primary granules stained negative or very weakly positive for myeloperoxidase. These abnormal granules were somewhat larger than normal (450 * 15 nm diameter), contained a flocculent material, and often appeared extracted. The RER was moderately dilated, and mitochondria were degenerated. Rare myelin figures were present. These promyelocytic cells could be distinguished from monocytic precursors that were smaller (8 to 10 pm in diameter), had a reniform nucleus, less prominent Golgi, less abundant RER, and smaller pleomorphic lysosomal granules (1 35 15 nm diameter) .
Myelocytes, metamyelocytes, and segmented neutrophils contained normal primary granules but appeared to have decreased numbers of secondary granules. However, due to paucity of these cells, an accurate quantitative assessment was not possible. Other cell lineages, including eosinophils, basophils, monocytes, and lymphocytes, appeared normal.
After GM-CSF treatment, there was an increase in bone marrow cellularity of up to 75%. This trend towards an increase in cellularity was confirmed by morphometric studies. The myeloid elements consisted mainly of granulocytic precursors, eosinophils, and monocytes; and the myeloid: erythroid cell ratio increased to 1.8. Electron microscopic examination of the posttreatment specimen showed no significant morphologic or morphometric changes in the myeloid series. However, the monocytes did show increased surface activity, displaying numerous filopodia1 cytoplasmic extensions (Fig 3C) . Morphologically and cytochemically, both monocytes and eosinophils appeared normal (Fig 3C and D) .
To evaluate the responsiveness in vivo of the hematopoietic progenitor cells, we assessed the frequency (number of colonies and/or clusters formed per number of cells plated) and cycling rates of the progenitor cells in vitro before and after administration of GM-CSF to the patient.
Before GM-CSF treatment, in vitro culture of bone marrow cells showed normal numbers and cycling rates for myeloid (CFU-GM) colonies ( Table 1) . Morphologic examination of these colonies revealed a normal distribution of granulocyte, macrophage, granulocyte-macrophage, and eosinophil (EOS) colonies ( Table 2) . However, most of the CFU-G and CFU-GM colonies and clusters contained neutrophils no more mature than metamyelocytes. Interestingly, the number of neutrophil and eosinophil colonies were similar whether we used GM-CSF or 5637 CM, which contains both GM-CSF and G-CSF (data not shown).
After GM-CSF treatment, significant increases were seen in the frequency of colony-forming cells per number of cells plated and in the cycling rates of CFU-GM (days 7 and 14) ( Table 1) . While some increases in the CFU-G colony frequency were observed on day 7 of culture, the predominant effect of in vivo GM-CSF treatment was on the frequency and cycling rates of the CFU-EOS ( Table 2 ).
Hemopoietic progenitor cell assays. Again, maturation in the granulocyte colonies was limited to the myelocyte-metamyelocyte stage.
To determine whether GM-CSF treatment had an impact on phagocytic function, we evaluated phagocytic and locomotive responses, and oxidative metabolism on the patient's cells. It was difficult to perform the complete set of functional assays before GM-CSF treatment because of a paucity of cells. Chemotaxis of the granulocyte fraction (which contained 74% neutrophils before GM-CSF) to HBSS and fMLP was depressed (Table 3) . After GM-CSF, purified granulocyte fractions contained 97% eosinophils. These cells were not as active as normal control neutrophils in chemotaxis to ACS, fMLP, and ACS + fMLP; however, they showed comparable activity with control eosinophilic cell populations (ie, control donor eosinophils had 40% to 60% of the chemotactic response of control donor neutrophils). The unstimulated locomotion of the patient's eosinophils was no different from control neutrophils (Table 3 ). The patient's cells were slower a t phagocytosis of S aureus but equally effective as control neutrophils. In contrast, the H,O, production rate by the patient's cells was significantly higher (3.5 times more) than that of control neutrophils (Table 3 ). This increase was comparable with that observed when control eosinophils were compared with control neutrophils in two experiments (ie, 31.7 k 7.2 and 16.9 f 3.4 nmol H,0,/2.5 x lo6 cells/min, respectively).
Phagocyte functions.

DISCUSSION
Treatment with GM-CSF in this patient with congenital neutropenia elicited a leukocytosis consisting primarily of Statistical analysis (Student's t test) for colony numbers compared the after (-3HTdr) to the before (-3HTdr) GM-CSF treatment groups. These values are shown for the colony (cluster) numbers in the after GMCSF treatment column. Analysis for % progenitors in S phase (in cycle) was done not to compare the after with the before GM-CSF-treatment groups, but rather to determine if the cycling rates shown were significant ones. If the numbers shown for % progenitors in S phase do not have a significance value, it means that these cells were not in cycle (P > 0.05).
Abbreviations: ND, not done, +'HTdr, treated with tritiated thymidine of high specific activity; -3HTdr, cells treated with saline. 'None refers to colonies stimulated by growth factors released endogenously from marrow cell preparations.
tThe % cells in S phase were calculated as described elsewhere" in which colony (cluster) numbers formed from cells treated with +'HTdr were subtracted from the numbers of those formed from cells treated with saline, and the resultant number was divided by numbers from cells of the -3HTdr group.
eosinophils and monocytes. The lack of a mature neutrophilic response in this patient was in stark contrast to our previous experience with acquired neutropenias,13-17 where proliferation of all myeloid lineages was accompanied by differentiation to mature cell types, predominantly neutrophils. Thus, the underlying basis for neutropenia in this patient must be different from that of other neutropenias. That all the myeloid lineages in this patient were capable of a proliferative response to GM-CSF is supported by several observations. First, the response in white blood cells was observed with each course of treatment. Second, the leukocytosis was sustained for the duration of each cycle.
Third, there was both in vivo and ex vivo evidence for proliferation of myeloid precursor cells of all lineages in the bone marrow. However, the proliferation along eosinophilic and monocytic pathways was coupled with maturation, while the neutrophilic response was truncated a t the myelocyte stage, and the abnormalities in granulogenesis persisted. Interestingly, the in vivo response to GM-CSF was mirrored in vitro where, despite an increase in absolute numbers and cycling rates of myeloid progenitors (predominantly eosinophils), the neutrophilic colonies exhibited a defect in maturation. Thus, the above findings suggest that the basis of neutropenia in this patient was not the result of a complete stem cell defect; rather, it reflects an inability of stimulated stem cells to complete terminal maturation along the neutrophilic series.
A lack of colony-stimulating activity in this disease has been suggested on the basis of observed responses to plasma inf~sion.'.'~ Interestingly, neutrophilic responses to recombinant human G-CSF treatment has recently been reported in patients with CN.25 The lack of a mature neutrophilic response to GM-CSF in this patient could be due to either the type of stimulating factor used or to an intrinsic cellular defect. The latter explanation appeared more likely, since in vitro culture of bone marrow cells from this patient using 5637-CM (a good source of G-CSF in addition to GM-CSF) and recombinant human G-CSF (H.E. Boxmeyer, S. VadhanRaj, unpublished data, 1989) did not correct the maturational defect. However, a neutrophilic response was subsequently observed after in vivo treatment with recombinant human G-CSF (L. Boxer, personal communication, August 1989). Despite the failure to produce a neutrophil-based leukocytosis, GM-CSF treatment was associated with healing of chronic infections/inflammatory foci in this patient, suggesting a clinical benefit from treatment. This effect may have been mediated through eosinophilic granulocytes (whose in vitro phagocytic and respiratory burst capabilities were documented) or activated monocytes.
In summary, although GM-CSF enhanced myelopoiesis along eosinophilic and monocytic pathways, neither in vitro nor in vivo exposure to it corrected the maturational abnormalities along the neutrophilic granulocyte pathway. Thus, in this patient, neutropenia appeared to be a result of an intrinsic defect in neutrophil maturation.
